Therapeutic value of orally administered silibinin in renal cell carcinoma: Manipulation of insulin-like growth factor binding protein-3 levels

BJU International

Volumn 100, Issue 2, 2007, Pages 438-444

  Cheung, Catherine W ^a   Taylor, Paul J ^a,b   Kirkpatrick, Carl M J ^a   Vesey, David A ^a   Gobe, Glenda C ^b   Winterford, Clay ^b   Nicol, David L ^a,b   Johnson, David W ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

IGFBP 3; Mice; Renal cell carcinoma; Silibinin; Therapeutics

Indexed keywords

INSULIN LIKE GROWTH FACTOR 3; MESSENGER RNA; SILIBININ; SOMATOMEDIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; DIET; DRUG DOSE ESCALATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; TANDEM MASS SPECTROMETRY; TUMOR ENGRAFTMENT; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CARCINOMA, RENAL CELL; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; KIDNEY NEOPLASMS; MALE; MICE; MICE, SCID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SILYMARIN;

EID: 34447130474     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07012.x     Document Type: Article

References (29)

1. Kovacs G, Akhtar M, Beckwith BJ et al. The Heidelberg classification of renal cell tumours. J Pathol 1997 183 : 131 3
2. Russo P. Localized renal cell carcinoma. Curr Treat Options Oncol 2001 2 : 447 55
3. Tian GG, Dawson NA. New agents for the treatment of renal cell carcinoma. Expert Rev Anticancer Ther 2001 1 : 546 54
4. Strohmaier WL. New treatment modalities - the urologist's view. Anticancer Res 1999 19 : 1605 9
5. Stassar MJ, Devitt G, Brosius M et al. Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer 2001 85 : 1372 82
6. Conover CA. Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism. Endocrinology 1992 130 : 3191 9
7. Pratt SE, Pollak MN. Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem Biophys Res Commun 1994 198 : 292 7
8. Cheung CW, Vesey DA, Nicol DL, Johnson DW. The roles of IGF-I and IGFBP-3 in the regulation of proximal tubule, and renal cell carcinoma cell proliferation. Kidney Int 2004 65 : 1272 9
9. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002 62 : 3063 9
10. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 2003 12 : 933 9
11. Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 2000 60 : 5617 20
12. Feher J, Cornides A, Pal J, Lang I, Csomos G. Liver cell protection in toxic liver lesion. Acta Physiol Hung 1989 73 : 285 91
13. Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 1994 27 : 105 12
14. Hruby K, Csomos G, Fuhrmann M, Thaler H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol 1983 2 : 183 95
15. Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther 1999 290 : 1375 83
16. Ahmad N, Gali H, Javed S, Agarwal R. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression. Biochem Biophys Res Commun 1998 247 : 294 301
17. Bhatia N, Zhao J, Wolf DM, Agarwal R. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett 1999 147 : 77 84
18. Kohno H, Tanaka T, Kawabata K et al. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer 2002 101 : 461 8
19. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993 123 : 1939 51
20. Saiki I, Naito S, Yoneda J, Azuma I, Price JE, Fidler IJ. Characterization of the invasive and metastatic phenotype in human renal cell carcinoma. Clin Exp Metastasis 1991 9 : 551 66
21. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998 77 : 880 3
22. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001 61 : 2035 63
23. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001 15 : 465 89
24. Agarwal C, Singh RP, Dhanalakshmi S et al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003 22 : 8271 82
25. Nickerson T, Huynh H, Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun 1997 237 : 690 3
26. Sprenger CC, Peterson A, Lance R, Ware JL, Drivdahl RH, Plymate SR. Regulation of proliferation of prostate epithelial cells by 1,25- dihydroxyvitamin D3 is accompanied by an increase in insulin-like growth factor binding protein-3. J Endocrinol 2001 170 : 609 18
27. Bhatia N, Agarwal C, Agarwal R. Differential responses of skin cancer-chemopreventive agents silibinin, quercetin, and epigallocatechin 3-gallate on mitogenic signaling and cell cycle regulators in human epidermoid carcinoma A431 cells. Nutr Cancer 2001 39 : 292 9
28. Zi X, Agarwal R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. Biochem Biophys Res Commun 1999 263 : 528 36
29. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1α,25-dihydroxyvitamin D (3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001 165 : 1319 24